| Urticaria and Angioedema |
1 |
1 |
| Urticaria |
0 |
0.99 |
| Chronic Urticaria |
0 |
0.74 |
| Acute Urticaria |
0 |
0.72 |
| Dermatographic Urticaria |
0 |
0.64 |
| Antihistamine |
0 |
0.36 |
| Pain Management |
0 |
0.12 |
| Washington |
0 |
0.12 |
| Child |
0 |
0.09 |
| Immunoglobulin E (IgE) |
0 |
0.09 |
| Vitamin |
0 |
0.09 |
| Immunoglobulin E (IgE) Antibody |
0 |
0.08 |
| Serum Immunoglobulin E (IgE) |
0 |
0.08 |
| Clinical Guidelines |
0 |
0.06 |
| Biologic Therapy |
0 |
0.05 |
| Neuromuscular Blocking Agents |
0 |
0.04 |
| Addiction |
0 |
0.03 |
| Adenovirus |
0 |
0.03 |
| Anaphylaxis |
0 |
0.03 |
| Antibiotics |
0 |
0.03 |
| Arthritis |
0 |
0.03 |
| Atopy |
0 |
0.03 |
| Autoimmune Disease |
0 |
0.03 |
| Bacteria |
0 |
0.03 |
| Biopsy |
0 |
0.03 |
| Corticosteroids |
0 |
0.03 |
| COVID-19 |
0 |
0.03 |
| Cyclosporine |
0 |
0.03 |
| Cytomegalovirus |
0 |
0.03 |
| Dermatoses |
0 |
0.03 |
| Diarrhea |
0 |
0.03 |
| Electronic Health Record (EHR) |
0 |
0.03 |
| Enteroviruses |
0 |
0.03 |
| Epstein-Barr Virus |
0 |
0.03 |
| Exercise |
0 |
0.03 |
| Genetics |
0 |
0.03 |
| Genomic Medicine |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Medical Innovations |
0 |
0.03 |
| Metabolism |
0 |
0.03 |
| Muscle |
0 |
0.03 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.03 |
| Office Visits |
0 |
0.03 |
| Opiate |
0 |
0.03 |
| Opioids |
0 |
0.03 |
| Pain |
0 |
0.03 |
| Patient Assessment |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Refractory |
0 |
0.03 |
| Residency |
0 |
0.03 |
| Rotavirus |
0 |
0.03 |
| Stress |
0 |
0.03 |
| Translational Research |
0 |
0.03 |